Janine Senz

TL;DR: These data implicate ARID1A as a tumor-suppressor gene frequently disrupted in ovarian clear-cell and endometrioid carcinomas.

TL;DR: The data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression, and two new RNA-editing events that recode the amino acid sequence of SRP9 and COG3 are revealed.

TL;DR: W Whole-transcriptome sequencing of four GCTs identified a single, recurrent somatic mutation (402C-->G) in FOXL2 that was present in almost all morphologically identified adult-type G CTs.

TL;DR: It is concluded that gene fusions are not infrequent events in ovarian cancer and that these events have the potential to substantially alter the expression patterns of the genes involved; gene fusion should therefore be considered in efforts to comprehensively characterize the mutational profiles of ovarian cancer transcriptomes.

TL;DR: Molecular classification of ECs can be achieved using clinically applicable methods on formalin-fixed paraffin-embedded samples, and provides independent prognostic information beyond established risk factors, and has potential in guiding treatment for individuals with endometrial carcinoma and in stratifying cases in future clinical trials.